Larry Norton Selected Research

Breast Neoplasms (Breast Cancer)

05/2008	Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
05/2008	Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
04/2008	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
04/2008	Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
04/2008	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840.
03/2008	The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
12/2007	Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
11/2007	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
10/2007	HER2 and response to paclitaxel in node-positive breast cancer.
08/2007	Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
05/2007	Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
01/2007	Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
12/2006	Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
11/2006	Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
08/2006	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
08/2006	A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
04/2006	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
01/2006	Use of dose-dense chemotherapy in the management of breast cancer.
09/2005	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
09/2005	Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
07/2005	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
07/2005	Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
04/2005	Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
04/2005	A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
03/2005	Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
03/2005	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
01/2005	Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
01/2005	Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
01/2005	Dose-dense adjuvant chemotherapy for primary breast cancer.
01/2005	Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
01/2005	Two regimens of docetaxel for metastatic breast cancer.
01/2005	Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
09/2004	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
09/2004	Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
09/2004	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.
06/2004	Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
06/2004	Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
11/2003	A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
04/2003	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
03/2003	Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
09/2002	Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
05/2002	Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
05/2002	Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
02/2002	Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
02/2002	High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.

Articles by Research Topic

Disease

45	Breast Neoplasms (Breast Cancer) 05/2008 - 02/2002
15	Neoplasms (Cancer) 05/2008 - 02/2002
9	Leukemia 05/2008 - 02/2002
3	Carcinoma (Carcinomatosis) 10/2005 - 05/2003
1	Amenorrhea 10/2005
1	Radiation Pneumonitis (Radiation Fibrosis) 09/2005

Drug/Important Bio-Agent (IBA)

11	Paclitaxel (Taxol)FDA LinkGeneric 05/2008 - 09/2002
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2008 - 02/2002
6	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2008 - 02/2002
4	Tamoxifen FDA LinkGeneric 04/2008 - 11/2003
4	letrozole (Femara)FDA Link 04/2008 - 11/2003
4	trastuzumab (Herceptin)FDA Link 04/2008 - 06/2004
4	taxaneIBA 10/2005 - 05/2002
3	Fluorouracil (Carac)FDA LinkGeneric 05/2008 - 02/2002
2	Filgrastim (Neupogen)FDA Link 05/2008 - 01/2007
2	Estrogens (Estrogen)FDA Link 05/2007 - 04/2006
2	TaxoidsIBA 09/2005 - 09/2004
1	capecitabine (Xeloda)FDA Link 04/2008
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2008
1	Phosphotransferases (Kinase)IBA 01/2008
1	Biological Tumor Markers (Tumor Markers)IBA 11/2007
1	flt3 ligand protein (flt3 ligand)IBA 10/2007
1	DNA (Deoxyribonucleic Acid)IBA 10/2007
1	Progesterone Receptors (Progesterone Receptor)IBA 05/2007
1	QS 21 (QS21)IBA 05/2007
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 05/2007
1	sialyl-Tn antigen-keyhole-limpet hemocyanin conjugateIBA 05/2007
1	Dihydrotachysterol (AT 10)IBA 01/2007
1	Epirubicin (Ellence)FDA LinkGeneric 01/2007
1	Interleukin-6 (Interleukin 6)IBA 12/2006
1	bevacizumab FDA Link 11/2006
1	cetuximab (Erbitux)FDA Link 08/2006
1	gemcitabine FDA Link 04/2005
1	imatinib (Gleevec)FDA Link 03/2005
1	docetaxel (Taxotere)FDA Link 01/2005
1	CreatinineIBA 01/2005
1	Keratins (Keratin)IBA 09/2004
1	celecoxib (Celebrex)FDA Link 06/2004
1	Methotrexate (Mexate)FDA LinkGeneric 05/2003
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2002
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2002

Therapy/Procedure

11	Adjuvant Chemotherapy 05/2008 - 03/2003
7	Drug Therapy (Chemotherapy) 08/2006 - 02/2002
1	Ovariectomy (Oophorectomy) 03/2008
1	Segmental Mastectomy (Lumpectomy) 09/2004
1	Mastectomy (Mammectomy) 09/2004
1	Combination Drug Therapy (Combination Chemotherapy) 04/2003
1	Transplants (Transplant) 02/2002